Skip to main content
. Author manuscript; available in PMC: 2015 May 27.
Published in final edited form as: Nature. 2014 Nov 27;515(7528):577–581. doi: 10.1038/nature13988

Figure 2. Mutant Lama4 and mAlg8 are therapeutically relevant d42m1-T3 TSMA.

Figure 2

a, Detection of mLama4 and mAlg8 bound to cellular H-2Kb by mass spectrometry. b, Time dependent tumour infiltration of mLama4- and mAlg8-specific CD8+ T cells (n=5), (top). Data represent means ± s.e.m of 5 independent experiments. Growth kinetics of d42m1-T3 and F244 during αPD-1 immunotherapy (n=5), (bottom). Data represent average tumour diameter ± s.e.m. and are representative of at least three independent experiments. c, IFN-γ ELISPOT analysis of peptide stimulated splenocytes from mice immunized with mLama4 or mAlg8 SLP plus polyI:C (n=3 mice per group). Data are means ± s.e.m. Representative of two independent experiments. Samples were compared using unpaired, two-tailed Student’s t test (*p<0.05, **p<0.01). d, Kaplan-Meier survival curves of d42m1-T3 tumour bearing mice (10 mice per group) therapeutically vaccinated with SLP vaccines plus poly I:C. mLama4 plus mAlg8 compared to HPV control: p=0.0002 [log-rank (Mantel-Cox) test]. Representative of two independent experiments. e, Cumulative data from two independent SLP therapeutic vaccine experiments using mice (7–10 per group) with d42m1-T3 or F244 tumours.